1Department of Obstetrics and Gynecology, Yeungnam University College of Medicine, Daegu, Korea
2Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea
3Department of Pathology, Yeungnam University College of Medicine, Daegu, Korea
Copyright © 2023 Yeungnam University College of Medicine, Yeungnam University Institute of Medical Science
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of interest
Mi Jin Gu has been an editorial board member of Journal of Yeungnam Medical Science since 2014. She was not involved in the review process of this manuscript. There are no other conflicts of interest to declare.
Funding
None.
Author contributions
Conceptualization: SYK, JHL, YJK, DHL; Data curation: SYK, JHL, MJG; Formal analysis: SYK, JHK, YJK, DHL; Methodology: JHK; Project administration: SYK; Visualization: SYK, JHL, JHK, YJK, MJG; Resources: YJK; Supervision: DHL; Validation: SYK, JHL; Writing-original draft: SYK, JHL; Writing-review & editing: JHL.
No. | Histopathology | Stagea) | Age (yr) | Size (cm) | First-line treatment | Treatment dateb) | Response to first-line treatment | DFS (mo) | Reference |
---|---|---|---|---|---|---|---|---|---|
1 | DLBCL (non-GCB type) | IE | 55 | 3.3 | Local excision+6 cycles of R-CHOP+radiation | May 26, 2020 | Complete remission | 29 mo | Current report |
2 | PCDLBCL-LT | IE | 38 | 1.0–2.0 | Radiation | NA | Complete remission | 84 yr | Ye et al. 2018 [4] |
3 | DLBCL (GCB type) | IE | 73 | 4×2×1.5 | Local excision | NA | Complete remission | 65 mo | Ye et al. 2018 [4] |
4 | DLBCL (GCB type) | IIE | 43 | 3.2 | Local excision+6 cycles of R-CHOP | NA | Complete remission | NA | Clemente et al. 2016 [5] |
5 | DLBCL | IIEA | 37 | 12×6 | 4 Cycles of R-CHOP+radiation | NA | Complete remission | 36 mo | El Kacemi et al. 2015 [8] |
6 | DLBCL | NA | NA | NA | NA | NA | NA | NA | Plaza et al. 2011 [9] |
7 | DLBCL | IE | 75 | NA | 5 Cycles of CHOP | NA | Recurrence | 10 mo | Signorelli et al. 2007 [3] |
8 | DLBCL | IE | 73 | 3×1.5 | Local excision+radiation | NA | Recurrence | 6 mo | Tjalma et al. 2002 [10] |
9 | DLBCL | IIE | 67 | NA | Chemotherapy+radiation | NA | NA | NA | Vang et al. 2001 [11] |
10 | DLBCL | IE | 71 | NA | NA | NA | NA | NA | |
11 | DLBCL | NA | 68 | NA | NA | NA | NA | NA | |
12 | DLBCL | IE | 64 | 3×2 | CHOP | NA | Complete remission | 12 mo | Iczkowski et al. 2000 [12] |
13 | DLBCL | IEB | 25 | 4×5.5 | Local excision+CHOP+radiation | Nov 1, 1991 | Recurrence | 6 mo | Kaplan et al. 1996 [13] |
14 | DLBCL | IE | 68 | 5×4.5×2.5 | Local excision | Mar, 1991 | NA | 14 mo | Nam et al. 1992 [14] |
DLBCL, diffuse large B-cell lymphoma; DFS, disease-free survival; GCB, germinal center B-cell-like; PCDLBCL-LT, primary cutaneous DLBCL leg type; NA, not applicable; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
a)According to the Ann Arbor staging criteria.
b)Start date of first-line treatment.
No. | Histopathology | Stage |
Age (yr) | Size (cm) | First-line treatment | Treatment date |
Response to first-line treatment | DFS (mo) | Reference |
---|---|---|---|---|---|---|---|---|---|
1 | DLBCL (non-GCB type) | IE | 55 | 3.3 | Local excision+6 cycles of R-CHOP+radiation | May 26, 2020 | Complete remission | 29 mo | Current report |
2 | PCDLBCL-LT | IE | 38 | 1.0–2.0 | Radiation | NA | Complete remission | 84 yr | Ye et al. 2018 [4] |
3 | DLBCL (GCB type) | IE | 73 | 4×2×1.5 | Local excision | NA | Complete remission | 65 mo | Ye et al. 2018 [4] |
4 | DLBCL (GCB type) | IIE | 43 | 3.2 | Local excision+6 cycles of R-CHOP | NA | Complete remission | NA | Clemente et al. 2016 [5] |
5 | DLBCL | IIEA | 37 | 12×6 | 4 Cycles of R-CHOP+radiation | NA | Complete remission | 36 mo | El Kacemi et al. 2015 [8] |
6 | DLBCL | NA | NA | NA | NA | NA | NA | NA | Plaza et al. 2011 [9] |
7 | DLBCL | IE | 75 | NA | 5 Cycles of CHOP | NA | Recurrence | 10 mo | Signorelli et al. 2007 [3] |
8 | DLBCL | IE | 73 | 3×1.5 | Local excision+radiation | NA | Recurrence | 6 mo | Tjalma et al. 2002 [10] |
9 | DLBCL | IIE | 67 | NA | Chemotherapy+radiation | NA | NA | NA | Vang et al. 2001 [11] |
10 | DLBCL | IE | 71 | NA | NA | NA | NA | NA | |
11 | DLBCL | NA | 68 | NA | NA | NA | NA | NA | |
12 | DLBCL | IE | 64 | 3×2 | CHOP | NA | Complete remission | 12 mo | Iczkowski et al. 2000 [12] |
13 | DLBCL | IEB | 25 | 4×5.5 | Local excision+CHOP+radiation | Nov 1, 1991 | Recurrence | 6 mo | Kaplan et al. 1996 [13] |
14 | DLBCL | IE | 68 | 5×4.5×2.5 | Local excision | Mar, 1991 | NA | 14 mo | Nam et al. 1992 [14] |
DLBCL, diffuse large B-cell lymphoma; DFS, disease-free survival; GCB, germinal center B-cell-like; PCDLBCL-LT, primary cutaneous DLBCL leg type; NA, not applicable; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone. According to the Ann Arbor staging criteria. Start date of first-line treatment.